Is Johnson & Johnson Stock a Buy?
Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However, Johnson & Johnson has encountered legal and regulatory headwinds in the past few years, giving investors pause. Furthermore, revenue growth generally hasn't been impressive, nor has Johnson & Johnson's stock market performance. Is the pharmaceutical giant still worth investing in?
Some might describe Johnson & Johnson's business as boring, but sometimes, that's not such a bad thing. Selling pharmaceutical products is a steady and reliable business even when the economy is down, since patients never stop needing potentially lifesaving medicines.
Johnson & Johnson's portfolio features more than 10 blockbuster drugs and spans several therapeutic areas, from infectious diseases to oncology.
Source Fool.com
